• Publications
  • Influence
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation
Objective: To explore whether the isocitrate dehydrogenase 1 (IDH1) or 1p/19q status determines the prognostic vs predictive role of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylationExpand
  • 146
  • 6
Aryl hydrocarbon receptor inhibition downregulates the TGF-β/Smad pathway in human glioblastoma cells
The dioxin/aryl hydrocarbon receptor (AhR) is a transcription factor, which has been attributed a role in human cancerogenesis, cell cycle progression and transforming growth factor-β (TGF-β)Expand
  • 74
  • 3
Transforming growth factor-β pathway activity in glioblastoma
Transforming growth factor (TGF)-β is a central molecule maintaining the malignant phenotype of glioblastoma. Anti-TGF-β strategies are currently being explored in early clinical trials. Yet, thereExpand
  • 54
  • 3
Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors
Purpose: Approximately 40% of all glioblastomas have amplified the EGFR gene, and about half of these tumors express the EGFRvIII variant. The prognostic role of EGFRvIII in EGFR-amplifiedExpand
  • 54
  • 3
Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy
The epidermal growth factor receptor vIII mutant (EGFRvIII) is found in ∼50% of all EGFR‐amplified glioblastomas and constitutes a tumor‐specific therapeutic target. To assess molecular testingExpand
  • 69
  • 2
Molecular characterization of long‐term survivors of glioblastoma using genome‐ and transcriptome‐wide profiling
The prognosis of glioblastoma, the most malignant type of glioma, is still poor, with only a minority of patients showing long‐term survival of more than three years after diagnosis. To elucidate theExpand
  • 78
  • 2
Modulation of TGF‐β activity by latent TGF‐β‐binding protein 1 in human malignant glioma cells
High biological activity of the transforming growth factor (TGF)‐β‐Smad pathway characterizes the malignant phenotype of malignant gliomas and confers poor prognosis to glioma patients. Accordingly,Expand
  • 40
  • 2
Glioma Cell Death Induced by Irradiation or Alkylating Agent Chemotherapy Is Independent of the Intrinsic Ceramide Pathway
Background/Aims Resistance to genotoxic therapy is a characteristic feature of glioma cells. Acid sphingomyelinase (ASM) hydrolyzes sphingomyelin to ceramide and glucosylceramide synthase (GCS)Expand
  • 11
  • 2
Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009
A population‐based analysis of patients with glioma diagnosed between 1980 and 1994 in the Canton of Zurich in Switzerland confirmed the overall poor prognosis of glioblastoma. To explore changes inExpand
  • 38
  • 1
NDRG1 prognosticates the natural course of disease in WHO grade II glioma
There is a lack of relevant prognostic and predictive factors in neurooncology besides mutation of isocitrate dehydrogenase 1, codeletion of 1p/19q and promoter hypermethylation ofExpand
  • 14
  • 1